Evaluation of Salivary Adseverin, 1-Alpha Defensin and sRANKL Levels of Individuals With Different Periodontal Diseases
Assessment of Saliva Adseverin,1-Alpha Defensin and sRANKL (Soluble RANKL) Levels In Individuals With Different Periodontal Diseases
1 other identifier
interventional
60
1 country
1
Brief Summary
: The aim of this study is; detection of Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in the biological samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 26, 2024
CompletedFirst Submitted
Initial submission to the registry
May 3, 2024
CompletedFirst Posted
Study publicly available on registry
May 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 24, 2025
CompletedDecember 9, 2025
May 1, 2024
10 months
May 3, 2024
December 2, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
The total amount of Adseverin in saliva
The total amount of Adseverin in saliva
24 hours after taking the clinical measurements at the first visit]
The total amount of 1-Alpha Defensin in saliva
The total amount of 1-Alpha Defensin in saliva
24 hours after taking the clinical measurements at the first visit
The total amount of sRANKL in saliva
The total amount of soluble RANKL in saliva
24 hours after taking the clinical measurements at the first visit
Study Arms (3)
Healthy Periodontium
EXPERIMENTALFull-mouth clinical periodontal measurements recorded and saliva obtain
Periodontitis
EXPERIMENTALFull-mouth clinical periodontal measurements recorded and saliva obtained.
Gingivitis
EXPERIMENTALFull-mouth clinical periodontal measurements recorded and saliva obtained.
Interventions
The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Eligibility Criteria
You may qualify if:
- Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) At least twenty permanent teeth in the mouth Non-smoker No medication for continuous use Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
- Not in pregnancy or lactation period. For the periodontitis group that has not received periodontal treatment in the last 6 months For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.
You may not qualify if:
- Any oral or systemic disease Regularly using a systemic medication During pregnancy or lactation Received periodontal treatment within the last 6 months. Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months Smokers are not included in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Izmir Katip Çelebi University Department of Periodontology
Izmir, Çiğli, 35640, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ayşe Efe
Izmir Katip Çelebi University Department of Periodontology İzmir, Çiğli, Turkey, 35640
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Assistant at Periodontology
Study Record Dates
First Submitted
May 3, 2024
First Posted
May 7, 2024
Study Start
April 26, 2024
Primary Completion
February 25, 2025
Study Completion
November 24, 2025
Last Updated
December 9, 2025
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF